No patient left behind—better treatments for resistant HIV infection
- 1 July 2007
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 370 (9581) , 3-5
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistanceAIDS, 2007
- Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trialThe Lancet, 2007
- Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trialThe Lancet, 2007
- Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trialThe Lancet, 2007
- Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsThe Lancet, 2007
- The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food EffectJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysisAIDS, 2007
- TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection ExperimentsJournal of Virology, 2005
- Discovery and Selection of TMC114, a Next Generation HIV-1 Protease InhibitorJournal of Medicinal Chemistry, 2004